Growth factors, PI3K/AKT/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now?

C Stefani, D Miricescu, II Stanescu-Spinu… - International journal of …, 2021 - mdpi.com
Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most
common cause of mortality and morbidity. The CRC incidence in adolescents, young adults …

Drug resistance in colorectal cancer: from mechanism to clinic

Q Wang, X Shen, G Chen, J Du - Cancers, 2022 - mdpi.com
Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …

Recent updates on the significance of KRAS mutations in colorectal cancer biology

L László, A Kurilla, T Takács, G Kudlik, K Koprivanacz… - Cells, 2021 - mdpi.com
The most commonly mutated isoform of RAS among all cancer subtypes is KRAS. In this
review, we focus on the special role of KRAS mutations in colorectal cancer (CRC), aiming …

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

S Camorani, M Passariello, L Agnello… - Journal of Experimental …, 2020 - Springer
Background Triple-negative breast cancer (TNBC) is a uniquely aggressive cancer with high
rates of relapse due to resistance to chemotherapy. TNBC expresses higher levels of …

Colorectal cancer development is affected by the ECM molecule EMILIN-2 hinging on macrophage polarization via the TLR-4/MyD88 pathway

E Andreuzzi, A Fejza, M Polano, E Poletto… - Journal of Experimental …, 2022 - Springer
Background Colorectal cancer is one of the most frequent and deadly tumors. Among the
key regulators of CRC growth and progression, the microenvironment has emerged as a …

Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma

M Yeon, Y Kim, HS Jung, D Jeoung - Frontiers in cell and …, 2020 - frontiersin.org
Therapies that target oncogenes and immune checkpoint molecules constitute a major
group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects …

[HTML][HTML] A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based …

MA Shadbad, Z Asadzadeh, A Derakhshani… - Biomedicine & …, 2021 - Elsevier
Tumoral programmed cell death ligand 1 (PD-L1) has been implicated in the immune
evasion and development of colorectal cancer. Although monoclonal immune checkpoint …

Emerging therapeutic agents for colorectal cancer

M Nalli, M Puxeddu, G La Regina, S Gianni, R Silvestri - Molecules, 2021 - mdpi.com
There are promising new therapeutic agents for CRC patients, including novel small-
molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC's …

Molecular Pathogenesis of Colorectal Cancer: Impact of Oncogenic Targets Regulated by Tumor Suppressive miR-139-3p

R Yasudome, N Seki, S Asai, Y Goto, Y Kita… - International Journal of …, 2022 - mdpi.com
We recently determined the RNA sequencing-based microRNA (miRNA) expression
signature of colorectal cancer (CRC). Analysis of the signature showed that the expression …

Regulatory mechanisms of PD-1/PD-L1 in cancers

X Lin, K Kang, P Chen, Z Zeng, G Li, W Xiong, M Yi… - Molecular Cancer, 2024 - Springer
Immune evasion contributes to cancer growth and progression. Cancer cells have the ability
to activate different immune checkpoint pathways that harbor immunosuppressive functions …